Themis Bioscience initiates Phase II trial of Chikungunya vaccine

Europe-based Themis Bioscience has started the Phase II clinical trial of its prophylactic vaccine candidate against Chikungunya fever by vaccinating the first patient.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news